MediGene to Present at the Needham Biotech Conference in New York
June 7, 2006
Webcast will be available at www.medigene.com
Martinsried/Munich - San Diego, - The German-American biotech company MediGene AG (Frankfurt, TecDAX, Prime Standard: MDG) announced today that the company will be presenting at the Needham Biotech Conference in New York, on Thursday June 15, 2006, at 3:00 p.m. local time, at The New York Palace Hotel. Alexander Dexne, Chief Financial Officer of MediGene AG, will give a review of the company and update the audience on current clinical, business and finance developments. The webcast of the presentation will be available on the internet at www.medigene.com.
MediGene possesses a mature drug pipeline with a drug available on the European market*. Another drug is undergoing approval procedure in the US (Polyphenon® E Ointment** for the treatment of genital warts) and several oncological drug candidates are in clinical development. In addition, MediGene owns cutting-edge platform technologies with the EndoTAG as well as the oncolytic HSV technologies. The drug candidate EndoTAG-1** (clinical phase II in pancreatic cancer) aims at “starving out” tumors by destroying the supplying blood vessels. It builds on the successful new therapeutic principle of anti-angiogenesis (inhibition of vascularization), and yet provides an innovative variation thanks to its novel mode of action (vascular disruptive agent). MediGene’s innovative oncolytic HSV (cancer-destroying herpes simplex viruses) are modified for the selective destruction of tumor cells without harming healthy tissue (phase I/II in glioma and liver metastases).
This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of MediGene as of the date of this release. These forward-looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. MediGeneTM and EndoTAGTM are trademarks of MediGene AG, Eligard® is a trademark of QLT USA, Inc., Polyphenon® E is a trademark of Mitsui Norin.
* For legal reasons, product name and indication are not mentioned on the internet (German Law on Drug Advertising)
** temporary name while under development
- ends -
MediGene AG Email: email@example.com
Fax: ++49 - 89 - 85 65- 2920
Julia Hofmann/Dr. Georg Dönges, Public Relations Tel.: ++49 - 89 - 85 65- 3317
Dr. Michael Nettersheim, Investor Relations Tel.: ++49 - 89 - 85 65- 2946
- Contact Information
- Julia Hofmann/Dr. Georg Dönges
- Public Relations
- MediGene AG
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.